HK2 and hepatocellular carcinoma: miR-125b can inhibit HCC cell proliferation by downregulating sirtuin7 [190], hexokinase 2 [191], and SIRT6 [192] and disrupting neovascularization to reduce HCC metastasis by downregulating the expression of Angpt2 (angiopoietin 2) [193].